Compare Novartis AG (NVS) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Tencent Music Entertainment Group - ADR — how do they compare? Novartis AG trades at $152.64 (market cap $295.37B), while Tencent Music Entertainment Group - ADR trades at $8.33 (market cap $16.09B). The key difference: Novartis AG is far larger — about 18.4× Tencent Music Entertainment Group - ADR's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NVS | TME | |
|---|---|---|
Market Cap | $295.37B | $16.09B |
Sector | Health | Media |
52-Week High | $168.62 | $26.36 |
52-Week Low | $119.31 | $8.16 |
Enterprise Value | $336.69B | $14.05B |
Dividend Yield | 3.07% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
TME stock trades at $9.90, up 3.88% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $8.9 billion (up 6% year-over-year) and net profit of $2.5 billion, beating EPS estimates. Financials show strong profitability with a net income margin of 26.28% and a P/E ratio of 10.29, indicating potential undervaluation. Recent news highlights mixed quarterly performance with revenue growth slowing but profit beating expectations.
The outlook for TME is cautiously optimistic, supported by solid fundamentals and bullish analyst sentiment, but risks include intensifying competition, user churn, and AI-related copyright issues. Upside potential exists from premium membership growth and ecosystem integration, though near-term volatility may persist due to market conditions and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
